Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis

Uluer, Ahmet; Waltz, David A.; Kalish, Leslie A.; Adams, S.; Gérard, Craig; Ericson, Dawn

doi:10.1016/j.jcf.2012.06.006

Cited by 12 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is of relevance as intravenous tobramycin can lead to systemic toxicity, such as ototoxicity and nephrotoxicity, which is uncommon in inhalation therapy. In a 6-month trial of inhaled tobramycin and amiloride in cystic fibrosis patients, no adverse effects were found [ 10 ]. In this case series, no treatment-related adverse events were recorded either.…”

mentioning

confidence: 99%

Eradication ofBurkholderia cepaciacomplex in cystic fibrosis patients with inhalation of amiloride and tobramycin combined with oral cotrimoxazole

et al. 2023

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Eradication ofBurkholderia cepaciacomplex in cystic fibrosis patients with inhalation of amiloride and tobramycin combined with oral cotrimoxazole

et al. 2023

View full text Add to dashboard Cite

show abstract

“…It is not known whether this microbiological effect would persist beyond the initial month of therapy. Tobramycin inhalation solution (TIS) has been studied in combination with inhaled amiloride in 12 CF patients with Burkholderia dolosa infection [12]. No differences in sputum bacterial density were noted after 6 months of treatment but it is unclear what drug concentrations were achieved in the lung with TIS as sputum tobramycin levels were not measured.…”

Section: Discussionmentioning

confidence: 99%

Pilot trial of tobramycin inhalation powder in cystic fibrosis patients with chronic Burkholderia cepacia complex infection

Waters

Yau

Beaudoin

et al. 2017

Journal of Cystic Fibrosis

View full text Add to dashboard Cite

There is no effective chronic suppressive therapy Burkholderia cepacia complex infection in cystic fibrosis (CF) patients. This was a pilot, open-label clinical trial of tobramycin inhalation powder (TIP) delivered via Podhaler twice daily for 28days in adults and children with CF and chronic B. cepacia complex infection in Toronto, Canada. A total of 10 subjects (4 pediatric, 6 adult patients) were treated. There was a mean drop of 1.4 log (CFU/ml) in sputum bacterial density (p=0.01) and sputum IL-8 levels decreased significantly after 28days of TIP (p=0.04). The mean relative change in FEV (L) from Day 0 to Day 28 of TIP administration was a 4.6% increase but this was not statistically significant. The majority of patients (70%) had no or mild adverse events.

show abstract

“…Using the methodology described, we selected 3 studies, 23 , 165 , 166 as illustrated in and . Only 1 study was characterized as an RCT.…”

Section: Methodsmentioning

confidence: 99%

Brazilian guidelines for the pharmacological treatment of the pulmonary symptoms of cystic fibrosis. Official document of the Sociedade Brasileira de Pneumologia e Tisiologia (SBPT, Brazilian Thoracic Association)

et al. 2023

View full text Add to dashboard Cite

Cystic fibrosis (CF) is a genetic disease that results in dysfunction of the CF transmembrane conductance regulator (CFTR) protein, which is a chloride and bicarbonate channel expressed in the apical portion of epithelial cells of various organs. Dysfunction of that protein results in diverse clinical manifestations, primarily involving the respiratory and gastrointestinal systems, impairing quality of life and reducing life expectancy. Although CF is still an incurable pathology, the therapeutic and prognostic perspectives are now totally different and much more favorable. The purpose of these guidelines is to define evidence-based recommendations regarding the use of pharmacological agents in the treatment of the pulmonary symptoms of CF in Brazil. Questions in the Patients of interest, Intervention to be studied, Comparison of interventions, and Outcome of interest (PICO) format were employed to address aspects related to the use of modulators of this protein (ivacaftor, lumacaftor+ivacaftor, and tezacaftor+ivacaftor), use of dornase alfa, eradication therapy and chronic suppression of Pseudomonas aeruginosa, and eradication of methicillin-resistant Staphylococcus aureus and Burkholderia cepacia complex. To formulate the PICO questions, a group of Brazilian specialists was assembled and a systematic review was carried out on the themes, with meta-analysis when applicable. The results obtained were analyzed in terms of the strength of the evidence compiled, the recommendations being devised by employing the GRADE approach. We believe that these guidelines represent a major advance to be incorporated into the approach to patients with CF, mainly aiming to favor the management of the disease, and could become an auxiliary tool in the definition of public policies related to CF.

show abstract

Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis

Abstract: Concurrent, continuous inhalation of amiloride and tobramycin for 6 months was not effective for the eradication of chronic B. dolosa airway infection in CF patients.

Cited by 12 publications

References 25 publications

Eradication ofBurkholderia cepaciacomplex in cystic fibrosis patients with inhalation of amiloride and tobramycin combined with oral cotrimoxazole

Eradication ofBurkholderia cepaciacomplex in cystic fibrosis patients with inhalation of amiloride and tobramycin combined with oral cotrimoxazole

Pilot trial of tobramycin inhalation powder in cystic fibrosis patients with chronic Burkholderia cepacia complex infection

Brazilian guidelines for the pharmacological treatment of the pulmonary symptoms of cystic fibrosis. Official document of the Sociedade Brasileira de Pneumologia e Tisiologia (SBPT, Brazilian Thoracic Association)

Contact Info

Product

Resources

About